Ribozyme-Mediated Cancer Gene Therapy

International Journal of Urology

Volumn 4, Issue 4, 1997, Pages 329-337

  Irie, Akira ^a   Bouffard, David Y ^a   Scanlon, Kevin J ^a  

^a BAYER AG   (Germany)

Author keywords

Bladder carcinoma; Gene therapy; H ras; Oncogenes; Ribozyme

Indexed keywords

DNA; RIBOZYME;

CHEMISTRY; GENE THERAPY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; REVIEW;

DNA, NEOPLASM; GENE THERAPY; HUMANS; NEOPLASMS; RNA, CATALYTIC;

EID: 0031178576     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1997.tb00203.x     Document Type: Review

References (90)

1. Cech TR, Zaug AJ, Grabowski PJ. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 1981;27:487-496.
2. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982;31:147-57.
3. Symons RH. Ribozymes. Curr Opin Struct Biol 1994; 4:322-330.
4. Breaker RR. In vitro selection of catalytic polynucleotides. Chem Rev 1997;97:371-390.
5. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987;328:596-600.
6. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988;334:585-591.
7. Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ. Therapeutic applications of ribozymes. Pharmacol Ther 1995;68:247-267.
8. Birikh KR, Heaton PA, Eckstein. The structure, function and application of the hammerhead ribozyme. Eur J Biochem 1997;245:1-16.
9. Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989;49:3713-3721.
10. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis cell. Cell 1990;61:759-767.
11. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:235-248.
12. Weinberg RA. Tumor suppressor genes. Science 1992;254:1138-1145.
13. Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, Vogelstein B, Stanbridge EJ. Progression of colorectal cancer associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992;12:1387-1395.
14. Kashani-Sabet M, Funato T, Tone T, Jiao L, Wang W, Yoshida E, Kashfian BI, Shitara T, Wu AM, Moreno JG, Traweek ST, Ahlering TE, Scanlon KJ. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev 1992;2:3-15.
15. Irie A, Kijima H, Ohkawa T, Bouffard DY, Suzuki T, Curcio LD, Holm PS, Sassani A, Scanlon KJ. Antioncogene ribozymes for cancer gene therapy. Advance Pharmacol 1997;40:207-257.
16. Hertel KJ, Pardi A, Uhlenbeck OC, Koizumi M, Ohtsuka E, Uesugi S, Cedergren R, Eckstein F, Gerlach WL, Hodgson R, Symons RH. Numbering system for the hammerhead. Nucleic Acids Res 1992;20:3252.
17. Pley HW, Flaherty KM, McKay DB. Three-dimensional structure of a hammerhead ribozyme. Nature 1994;372:68-74.
18. Scott WG, Klug A. Ribozymes: structure and mechanism in RNA catalysis. Trends Biochem Sci 1995; 21:220-224.
19. Scott WG, Finch JT, Klug A. The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage. Cell 1995;81:991-1002.
20. Sigurdsson STH, Tuschl T, Eckstein F. Proving RNA tertiary structure: interhelical crosslinking of the hammerhead ribozyme. RNA 1995;1:575-583.
21. McKay DB. Structure and function of the hammerhead ribozyme: an unfinished story. RNA. 1996;2:395-403.
22. Ruffner DE, Stormo GD, Uhlenbeck OC. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 1990;29:10695-10702.
23. Perriman R, Delves A, Gerlach WL. Extended target-site specificity for a hammerhead ribozyme. Gene 1992; 113:157-163.
24. Pyle A. Ribozymes: a distinct class of metalloenzymes. Science 1993;261:709-714.
25. Barbacid M. ras genes. Annu Rev Biochem 1987; 56:779-827.
26. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689.
27. Egan SE, Weinberg RA. The pathway to signal achievement. Nature 1993;365:781-783.
28. Koizumi M, Hayase Y, Iwai S, Kamiya H, Inoue H, Ohtsuka E. Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res 1989;17:7059-7071.
29. Goldfarb M, Shimizu K, Perucho M, Wigler M. Isolation and preliminary characterization of a transforming gene from T24 bladder carcinoma cells. Nature 1982; 296:404-409.
30. Shih C, Weinberg RA. Isolation and transforming sequence from a human bladder carcinoma cell line. Cell 1982;29:161-169.
31. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR, Chang EH. Mechanism of activation of a human oncogene. Nature 1982;300:143-149.
32. Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982;300:149-152.
33. Taparowsky E, Suard Y, Fasano O, Shimizu K, Goldfarb M, Wigler M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 1982;300:762-765.
34. Fujita J, Srivastava SK, Kraus MH, Rhim JS, Tronick SR, Aaronson SA. Frequency of molecular alterations affecting ras proto-oncogenes in human urinary tract tumors. Proc Natl Acad Sci USA 1985;82:3879-3853.
35. Fujita J, Yoshida O, Yuasa Y, Rhim JS, Hatanaka M, Aaronson SA. Ha-ras oncogenes are activated by somatic alteration in human urinary tract tumors. Nature 1984;309:464-466
36. Visvanathan KU, Pocock RD, Summerhayes IC. Preferential and novel activation of H-ras in human bladder carcinomas. Oncol Res 1988;53:133-139.
37. Burchill SA, Lunec J, Mellon K, Neal DE. Analysis of Ha-ras mutations in primary human bladder tumors. Br J Cancer 1991;63(supp):162.
38. Czerniak B, Cohen GL, Etkind P, Deitch D, Simmons H, Herz F, Koss, LG. Concurrent mutation of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol 1992;23:1199-1204.
39. Knowles MA, Williamson M. Mutations of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 1993;53:133-139.
40. Levesque P, Ramchurren N, Saini K, Joyce A, Libertino J, Summerhayes IC. Sequencing of human bladder tumors and urine sediments for the presence of H-ras mutations. Int J Cancer 1993;55:785-790.
41. Burchill SA, Neal DE, Lunec J. Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. Br J Urol 1994;73:516-521.
42. Uchida T, Wada C, Ishida H, Egawa S, Ao T, Yokoyama E, Koshiba K. Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors. Urol Int 1995;55:63-67.
43. Saito S, Hata M, Fukuyama R, Sakai K, Kudoh J, Tazaki H, Shimizu N. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int J Urol 1997;4:178-185.
44. Greig RG, Koestler TP, Trainer DL, Corwin SP, Miles L, Kline T, Sweet R, Yokoyama S, Poste G. Tumorigenic and metastatic properties of "normal" and ras-transfected NIH/3T3 cells. Proc Natl Acad Sci USA 1985;82:3698-3701.
45. Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci USA 1990; 87:9047-9051.
46. Funato T, Shitara T, Tone T, Jiao L, Kashani-Sabet M, Scanlon KJ. Suppression of H-ras-mediated transformation in NIH 3T3 cells by a ras ribozyme. Biochem Pharmacol 1994;48:1471-1475.
47. Tone T, Kashani-Sabet M, Funato T, Shitara T, Yoshida E, Kashfian BI, Horng M, Fodstad O, Scanlon KJ. Suppression of EJ cells tumorigenicity. In Vivo 1993;7:471-476.
48. Feng M, Carbrera G, Deshane J, Scanlon KJ, Curiel DT. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of anti-ras ribozyme. Cancer Res 1995;55:2024-2028.
49. Bass C, Cabrera G, Elgavish A, Robert B, Siegal GP, Anderson SC, Maneval DC, Curiel DT. Recombinant adenoviral-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 1995;2:97-104.
50. Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J Invest Dermatol 1996; 106:1-6.
51. Ohta Y, Tone T, Shitara T, Funato T, Jiao L, Kashfian BI, Yoshida E, Horng M, Tsai P, Lauterbach K, Kashani-Sabet M, Florenes VA, Fodstad OY, Scanlon KJ. H-ras ribozyme mediated alteration of the human melanoma phenotype. Annu New York Acad Sci 1994;716:242-253.
52. Ohta Y, Kijima H, Ohkawa T, Kashani-Sabet M, Scanlon KJ. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res 1996;24:938-942.
53. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994;54:900-902.
54. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
55. Kijima H, Bouffard DY, Scanlon KJ. Ribozyme-mediated reversal of human pancreatic carcinoma phenotype. In: Ikehara S (ed) Proceedings of international symposium on bone marrow transplantation. Berlin: Springer, 1996:153-163.
56. Kurzock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988;319:990-998.
57. Wright L, Wilson SB, Milliken S, Biggs J, Kearney P. Ribozyme mediated cleavage of the bcr/abl transcription expressed in chronic myeloid leukemia. Exp Hematol 1993;21:1714-1718.
58. Pachuk CJ, Yoon K, Moelling K, Coney LR. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to noncontiguous sequences. Nucleic Acids Res 1993;22:301-307.
59. Leopold LH, Shore SK, Newkirk TA, Reddy RMV, Reddy EP. Multi-unit ribozyme mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 1995; 85:2162-2170.
60. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus type 16 and 18 E6 protein with p53. Science 1990;248:76-79.
61. He Y-K, Lu CD, Qi G. In vitro cleavage of HPV16 E6 and E7 RNA fragments by synthetic ribozymes and transcribed ribozymes from RNA-trimming plasmids. FEBS Lett 1993;322:21-24.
62. Lu CD, Chatterjee S, Brar D, Wong KK Jr. Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Cancer Gene Ther 1994; 1:267-277.
63. Czubayko F, Riegel AT, Wellstein A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem 1994; 269:21358-21363.
64. Mælandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad Ø. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 1996; 56:5490-5498.
65. Ishida H, Kijima H, Ohta Y, Kashani-Sabet M, Scanlon KJ. Mechanisms of cisplatin resistance and its reversal in human tumors. In: Kallen JA (ed) Alternative mechanisms of multidrug resistance in cancer. Boston: Birkhauser, 1995:225-264.
66. Ohkawa T, Kijima H, Irie A, Horng G, Kaminski A, Tsai J, Kashfian BI, Scanlon KJ. Oligonucleotide modulation of multidrug resistance gene expression. In: Gupta S, Tsuruo T (eds) Multidrug resistance in cancer cells: cellular, biochemical, molecular and biological aspects. England: John Wiley and Sons, 1996:413-433.
67. Gros P, Croop J, Roninson I, Varshavsky A, Housman DE. Isolation and characterization of DNA sequences amplified in multidrug resistant hamster cells. Proc Natl Acad Sci USA 1986;83:337-341.
68. Roninson IB, Chin JE, Choi K, Gros P, Housman DE, Fojo A, Gottesman MM, Pastan I. Isolation of human mdr DNA sequences amplified in multidrug resistant KB carcinoma cells. Proc Natl Acad Sci USA 1986;83:4538-4542.
69. Bouffard DY, Ohkawa T, Kijima H, Irie A, Suzuki T, Curcio LD, Holm PS, Sassani A, Scanlon KJ. Oligonucleotide modulation of multidrug resistance. Eur J Cancer 1996;32A:1010-1018.
70. Kobayashi H, Dorai T, Holland JF, Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by MDR-1(PGY-1) ribozyme. Cancer Res 1994;54:1271-1275.
71. Scanlon KJ, Ishida H, Kashani-Sabet M. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci USA 1994;91:11123-11127.
72. Bertrand E, Rossi JJ. Facilitation of hammerhead ribozymes catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J 1994;13:2904-2912.
73. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci USA 1991;88:6921-6925.
74. Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 1996; 23:154-158.
75. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993; 53:962-967.
76. Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, Tso C, DeKernion JB, Belldegrun AS. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Human Gene Ther 1995;6:1417-1426.
77. Zhao JJ, Pick L. Generating loss-of-function phenotypes of the fushi tarazu gene with targeted ribozyme in Drosophila. Nature 1993;365:448-451.
78. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1991;88:2726-2730.
79. Acsadi G, Dickson G, Love DR, Jani A, Walsh FS, Gurusignhe A, Wolff JA, Davies KE. Human dystrophin expression in mdx mice after intracellular injection of DNA constructs. Nature 1991;352:815-818.
80. Acsadi G, Jiao S, Jani A, Duke D, Williams P, Chong W, Wolff JA. Direct gene transfer and expression into heart in vivo. New Biology 1991;3:71-81.
81. Lichtenberg D. Liposomes: preparation, characterization, and preservation. Methods Biochem Anal 1988; 33:337-468.
82. Felgner JH, Kumar R, Sridhar CM, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994;269:2550-2561.
83. Zenke M, Steinlein P, Wagner E, Cotten M, Beug H, Birnstiel ML. Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc Natl Acad Sci USA 1990;87:3655-3659.
84. Wu GY, Wu CH. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem 1987;262:4429-4432.
85. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther 1994;1:51-64.
86. Weitzman MD, Wilson JM, Eck SL. Adenovirus vectors in cancer gene therapy. In: Sobol RE, Scanlon KJ (eds) The internet book of gene therapy. Stamford: Appleton & Lange, 1995:17-25.
87. Mufson MA, Belshe RB. A review of adenoviruses in the etiology of acute hemorrhagic cystitis. J Urol 1976;115:191-194.
88. Morris BD, Drazan KE, Csete ME, Werthman PE, Van Bree MP, Rosenthal T, Shaked A. Adenoviral-mediated gene transfer to bladder in vivo. J Urol 1994;153:506-509.
89. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shaked A. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 1996;155:753-756.
90. Bartlett JS, Quattrocchi KB, Samulski RJ. The development of adeno-associated virus as a vector for cancer gene therapy. In: Sobol RE, Scanlon KJ (eds) The internet book of gene therapy. Stamford: Appleton & Lange, 1995:27-39.